2. UroToday Home
  3. Video Lectures

CRPC with Bone Metastases Videos

2024 NCCN Guidelines: Managing Bone Health in Prostate Cancer Patients - Rashid Sayyid & Zachary Klaassen
July 26, 2024
Details
2024 NCCN Guidelines: Preventing Skeletal Events in Prostate Cancer - Rashid Sayyid & Zachary Klaassen
July 25, 2024
Details
Optimizing Multi-Disciplinary Care Teams for Radiopharmaceutical Administration - Neal Shore
January 5, 2023
Details
The Correlation Between Alkaline Phosphatase Decline and Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer in the REASSURE Study - Nicholas James
January 5, 2023
Details
A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore
October 17, 2022
Details
Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff
October 16, 2022
Details
Optimal Sequencing - Should It Include Radium Given Lutetium? - Joe O'Sullivan
October 16, 2022
Details
Is There Still a Role for Radium-223? APCCC 2022 Presentation - Neal Shore
September 14, 2022
Details
Importance of Lifestyle and Prevention of Complications in Advanced Prostate Cancer: How to Take Care of the Bones? APCCC 2022 Presentation - Oliver Sartor
September 1, 2022
Details
Treatment Sequencing with Radium-223 in Symptomatic Disease - Fred Saad
July 2, 2022
Details
Identifying the Right Patients for Treatment with Radium-223 for mCRPC - Brenda Martone
June 22, 2022
Details
Radium-223 Plus Enzalutamide versus Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal & Ben Maughan
January 11, 2022
Details
A Real-World Analysis of Pain Efficacy of Radium-223 Treatment Among Patients With Metastatic Castration-Resistant Prostate Cancer and Symptomatic Bone Metastases – the REASSURE Trial – Celestia Higano
December 27, 2021
Details
Prospective Analysis of The Effect of Germline Mutations on Outcomes for mCRPC Patients Treated With Radium-223 (PRORADIUM) – Elena Castro
November 9, 2021
Details
Real-World Data in Second-Line Treatment Progressing mCRPC – Oliver Sartor
November 3, 2021
Details
Real-World Safety and Effectiveness of Radium-223 in Japanese Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastasis - Beyond the Abstract
August 25, 2021
Details
Radium-223 Treatment for Metastatic Prostate Cancer - Ila Sethi
August 17, 2021
Details
The NCCN Guidelines on the Use of Radium-223 in Prostate Cancer - Tanya Dorff
August 12, 2021
Details
Patient Assessment and Treatment Strategies for mCRPC - William Oh
July 26, 2021
Details
Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life - Brenda Martone
June 27, 2021
Details
Ensuring Patients Have Access to Radium-223 as a Therapeutic Option: The DORA Trial - Michael Morris
June 22, 2021
Details
The Importance of Bone-Protecting Agents When Treating mCRPC with Bone Metastatic Disease The PEACE III Trial – Silke Gillessen
June 21, 2021
Details
The Effect of Mandated Bone Protective Agents on Fracture Risk With Longer Follow-Up (EORTC 1333 / PEACE III Trial) – Fred Saad
June 8, 2021
Details
Changing the Mechanism of Action in The Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) - Phillip Koo
June 24, 2020
Details
Novel Radiopharmaceuticals In Development For Treatment in Advanced Prostate Cancer - Michael Morris
May 31, 2020
Details
Bone Health and Osteoclast Targeted Therapies in Advanced Prostate Cancer - Matthew Smith
May 1, 2020
Details
Real-World Clinical Outcomes with Radium-223 in Metastatic Castration-resistant Prostate Cancer - Neal Shore
March 8, 2020
Details
Bone Health Agents in Patients with Castrate-Resistant Prostate Cancer - Bertrand Tombal
January 16, 2020
Details
Assessing the Aging Population and Treatment Considerations for Prostate Cancer - Joe O'Sullivan
October 31, 2019
Details
The Risk of Dose De-intensifying Treatment, Bone Health in Prostate Cancer - Fred Saad
September 25, 2019
Details
Radium-223 and Bone Health Agents: Lessons Learned Presentation - Oliver Sartor
September 24, 2019
Details
Anti-Resorptive Therapy to Reduce Skeletal-Related Events Risk in Men with Bone-Metastatic CRPC Presentation - Chris Parker
September 20, 2019
Details
Antiresorptive Therapy to Reduce SRE Risk For The Majority of Men with CRPC and Bone Metastases Presentation - Bertrand Tombal
September 20, 2019
Details
Prevention and Treatment of Osteoporosis Presentation - Fred Saad
September 5, 2019
Details
Sequencing Treatments in Metastatic Prostate Cancer - Evan Yu
May 10, 2019
Details
Real World Treatment Experience with Radium-223 - Dan George
May 3, 2019
Details
Contemporary Treatment of Castration-Resistant Prostate Cancer (CRPC) - Fred Saad
July 9, 2019
Details
Alpha Particles as Radiopharmaceuticals in the Treatment of Bone Metastases
February 8, 2019
Details
Current Management of Bone Metastatic Castrate-Resistant Prostate Cancer : Panel Discussion
January 24, 2019
Details
Bone Health in Prostate Cancer - A Conversation with Neal Shore and Oliver Sartor
January 20, 2019
Details
A Nuclear Radiologist’s Perspective on Bone Targeted Therapies- Phillip Koo
November 7, 2018
Details
Decision Making When Treating Prostate Cancer - Silke Gillessen
November 5, 2018
Details
ERA 223: Presentation Summary from ESMO 2018 - Fred Saad
November 1, 2018
Details
The Role of Bone Health Agents in Patients with Prostate Cancer - Tia Higano
October 31, 2018
Details
A Renewed Analysis of ERA 223 - Fred Saad
October 27, 2018
Details
Prostate Cancer Osteomimicry in Circulating Tumor Cells in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) - Andrew Armstrong
July 31, 2018
Details
Updates on Health-Related Quality-of-Life (HRQoL) analyses in GU Oncology - Cora Sternberg
July 24, 2018
Details
The State of Nuclear Medicine in the Treatment of Prostate Cancer - Interview with Oliver Sartor
June 25, 2018
Details
Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo
June 4, 2018
Details